LGD-2226 vs Ostarine

LGD-2226 wins for: users chasing anabolic benefit with minimal androgenic burden, particularly where bone density and muscle preservation are the priority—plus animal data suggesting libido preservation at effective doses. Its niche profile may appeal in specialized research contexts where prostate-sparing AR modulation is needed and mainstream SARMs are too androgenic or suppressive.

Ostarine wins for: overall reliability, widely documented dosing, and broad-spectrum muscle preservation. The protocol is community-validated, sourcing is easy, and clean results are expected—making it the de facto leader for first SARM cycles, recomp, and diet-phase support. It also has the edge for predictable safety and fewer sourcing headaches.

Pick LGD-2226 if:

• The research goal is maximizing bone mineral density along with muscle, especially in androgen-deprived models.
• Libido and sexual behavior must be preserved while suppressing androgenic side effects (prostate, scalp).
• There's an interest in exploring advanced or rare SARM protocols that are not already saturated in the literature.
• Mainstream SARMs (LGD-4033, RAD-140) induce unwanted suppression or androgenic effects at needed doses.
• The context is a multi-compound stack for intelligent androgen receptor modulation (e.g., combining with MK-677 for GH synergy).

Pick Ostarine if:

• Reliable, community-validated lean mass retention or mild gains are the main research endpoint.
• The priority is muscle preservation on a cut, with minimal side effect profile.
• Simple, predictable sourcing and protocol design are desired.
• The research protocol is a first SARM cycle or between-cycle bridge.
• An established safety and suppression dataset is preferred for protocol planning.